BriaCell To Initiate Phase 2 Trial With Targeted Cancer Immunotherapy

April 6, 2016 - PRLog -- Earlier this week, BriaCell Therapeutics Corp (BCT.V) (BCTXF) announced it is planning to initiate a Phase 1/2 study with BriaVax™ in the second quarter 2016. BriaVax™  is a proprietary whole tumor cell therapeutic vaccine designed to treat late-stage metastatic cancers, including breast and ovarian cancer. The trial is expected to enroll up to 24 late-stage cancer patients at several university hospitals in the U.S.

Treatment with BriaVax™ is the result of decades of clinical investigation and research into therapeutic cancer vaccines and the use of an allogeneic whole cell breast tumor line that overexpresses a clinically validated tumor antigen in HER-2/neu. Just recently, the company announced it has discovered a gene signature indicative of clinical response to BriaVax™. This should work to dramatically improve outcome in future clinical studies.

To read more about BriaCell Therapeutics and this important clinical study, please see the full report here >> http://www.bionapcfa.com/2016/04/briacell-to-initiate-phase-2-trial-with.html

----------

Please see our Disclaimer.

Contact
Jason Napodano, CFA
***@bionapcfa.com
Photos: (Click photo to enlarge)



Read Full Story - BriaCell To Initiate Phase 2 Trial With Targeted Cancer Immunotherapy | More news from this source

Press release distribution by PRLog